ArticleCancers2025

Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study.

Anna Sureda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.